John Bossaer

OncoPharm

Science EN ↓ 433 episodes

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Author

John Bossaer

Episodes

Landmarks in Oncology Pharmacy: MOPP 19.01.2018 17:33

The Landmarks series continues with DeVita's original MOPP (Hodgkin's Disease) publication from 1970. Discussion points include WBC monitoring, why cyclophosphamide isn't included, and wigs.

Foundations in Oncology Pharmacy: Cisplatin 12.01.2018 14:55

The Foundations in Oncology Pharmacy series begins with the penicillin of oncology: cisplatin. Discussion of its history, current uses, & toxicities. Perfect for those new to oncology pharmacy.

Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML) 05.01.2018 20:20

Review of recent FDA action re: oncology pharmacy including review of the APHINITIY trial and pertuzumab's subsequent approval in the adjuvant setting. Also, the nilotinib label change allowing for discontinuation in CML patients is discussed.

Landmarks in Oncology Pharmacy: Acute Leukemia in 1958 01.01.2018 14:22

In the 1st of the Landmarks series, we look back at a pivotal article published in Blood in 1958 on the treatment of acute leukemia.

2017 Was A Good Year 18.12.2017 23:39

2017 saw A LOT of #oncopharm approvals. Oncology pharmacist & educator John Bossaer runs through some of the most notable oncology pharmacy trends of the year, include CAR-T cell therapy

Tales of Brave Iressa 30.11.2017 17:25

Discussion of gefitinib's journey back to the market and lessons to be learned from it by oncology pharmacist & educator John Bossaer.

Adjuvant TKIs? 17.11.2017 19:17

Recent FDA updates & a brief discussion about adjuvant TKI use in solid tumors.

Acalabrutinib 01.11.2017 13:21

Oncology Pharmacy Podcast discussing the FDA-approval of acalabrutinib